AN2 Therapeutics (ANTX) TD Cowen 45th Annual Healthcare Conference summary

Corporate strategy and platform

• Focuses on boron chemistry to target undruggable proteins, with a track record of FDA approvals and a productive drug discovery platform.

• Pipeline includes infectious disease and oncology programs, with expansion into oncology based on platform versatility.

• Cash runway supports operations and development through 2027.

Pipeline highlights and clinical development

• Lead asset epetraborole targets NTM lung disease, with phase III data unblinding planned for Q2 this year.

• Chagas disease program advancing, with phase I completion and phase II initiation planned for next year.

• Melioidosis program to start phase II this year, with potential for priority review voucher and government stockpiling.

• Oncology candidates expected to enter development this year, leveraging boron chemistry for novel targets.

NTM lung disease program details

• Epetraborole offers an oral alternative to current inhaled therapies, targeting a $1B+ refractory market.

• Phase II/III study enrolled highly refractory, multi-drug resistant patients, showing statistically significant PRO results.

• Updated statistical analysis plan submitted to FDA; NDA preparation underway pending phase III results.

• Front-line NTM treatment would use QOL-B as primary endpoint, with higher expected success rates than refractory cases.